FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 10, 2017

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On November 10, 2017, Second Sight Medical Products, Inc. (the “Company” or “we”) issued a press release announcing that the Ontario Health Technology Advisory Committee (OHTAC) recommends Public Funding for the Company’s Argus^® II Retinal Prosthesis System.

OHTAC, in Ontario Canada, is recognized as a global leader in medical device health technology assessment. This positive, evidence-based recommendation will be shared with health systems internationally to facilitate improved global patient access to this important technology.

A copy of our press release entitled “Ontario Health Technology Advisory Committee Recommends Public Funding for Second Sight’s Argus II Retinal Prosthesis System” is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 10, 2017

SECOND SIGHT MEDICAL PRODUCTS, INC.